Gilead Sciences, Inc. $GILD Stock Holdings Increased by Sigma Planning Corp

Key Points

• Sigma Planning increased its Gilead stake 47.5% in Q4 to 28,061 shares (~$3.44M), and other large institutions — including Vanguard (121,097,336 shares) and Massachusetts Financial Services (4,223,304 shares) — boosted positions, leaving institutional ownership at about 83.7%.
• Insiders have been net sellers: CFO Andrew D. Dickinson sold 3,000 shares and CEO Daniel P. O’Day sold 115,640 shares (under a 10b5‑1 plan), with insiders offloading 178,640 shares (~$26.6M) over the last quarter while retaining just 0.30% ownership.
• Corporate catalysts include an FDA priority review for Gilead’s once‑daily bictegravir+lenacapavir HIV regimen and completion of the ~ $7.8B Arcellx acquisition, while the company also raised its quarterly dividend to $0.82 (annualized $3.28; ~2.5% yield).

Sigma Planning Corp lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 47.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 28,061 shares of the biopharmaceutical company's stock after purchasing an additional 9,038 shares during the quarter. Sigma Planning Corp's holdings in Gilead Sciences were worth $3,444,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in GILD. Massachusetts Financial Services Co. MA lifted its position in shares of Gilead Sciences by 3,763.8% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company's stock worth $518,368,000 after purchasing an additional 4,113,999 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Gilead Sciences by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company's stock worth $14,863,487,000 after purchasing an additional 2,113,692 shares in the last quarter. First Trust Advisors LP lifted its position in shares of Gilead Sciences by 154.3% in the third quarter. First Trust Advisors LP now owns 3,089,283 shares of the biopharmaceutical company's stock worth $342,910,000 after purchasing an additional 1,874,508 shares in the last quarter. Invesco Ltd. lifted its position in shares of Gilead Sciences by 12.0% in the third quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company's stock worth $1,680,505,000 after purchasing an additional 1,618,453 shares in the last quarter. Finally, Danske Bank A S purchased a new stake in shares of Gilead Sciences in the third quarter worth approximately $133,049,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total transaction of $422,880.00. Following the transaction, the chief financial officer owned 176,191 shares in the company, valued at $24,835,883.36. This trade represents a 1.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 115,640 shares of the stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $150.00, for a total value of $17,346,000.00. Following the transaction, the chief executive officer owned 613,912 shares in the company, valued at approximately $92,086,800. This trade represents a 15.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 178,640 shares of company stock worth $26,584,250. Insiders own 0.30% of the company's stock.

Gilead Sciences Trading Up 0.6%

NASDAQ:GILD opened at $131.65 on Friday. The stock's 50 day moving average price is $140.49 and its 200 day moving average price is $132.35. Gilead Sciences, Inc. has a 52 week low of $95.29 and a 52 week high of $157.29. The company has a market capitalization of $163.41 billion, a P/E ratio of 19.45, a P/E/G ratio of 1.73 and a beta of 0.39. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts' consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter in the prior year, the company posted $1.90 earnings per share. The firm's revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, research analysts forecast that Gilead Sciences, Inc. will post 8.62 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were issued a $0.82 dividend. This is an increase from Gilead Sciences's previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date was Friday, March 13th. Gilead Sciences's dividend payout ratio is currently 48.45%.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: FDA gives priority review to Gilead’s once‑daily bictegravir + lenacapavir HIV regimen, shortening the path to U.S. commercialization if approved — a clear revenue and de‑risking catalyst. Read More.
• Positive Sentiment: Gilead completed the Arcellx acquisition (~$7.8B), adding the anito‑cel cell therapy to its oncology pipeline and boosting longer‑term growth optionality beyond antivirals. Read More.
• Positive Sentiment: Analyst bullishness: Morgan Stanley and other shops have raised price targets/ratings recently, signaling analyst support that can attract buyers. Read More.
• Neutral Sentiment: Gilead scheduled presentations at several investor conferences (BofA, RBC, Bernstein, Goldman Sachs) — increases visibility and provides opportunities to update guidance/portfolio progress but is informational rather than a direct catalyst. Read More.
• Neutral Sentiment: Pre‑earnings coverage highlights HIV franchise strength versus cell‑therapy cost/headwinds; Wall Street expects modest earnings growth into the next print — sets expectations for the upcoming report. Read More.
• Negative Sentiment: CEO Daniel O’Day sold shares under a Rule 10b5‑1 plan (recent transactions disclosed), which can create short‑term headline pressure even if planned. Read More.
• Negative Sentiment: Advocacy group AHF filed a shareholder resolution seeking more transparency on patent exclusivities — raises governance/IP scrutiny that could produce regulatory or PR noise around future exclusivity‑dependent revenues. Read More.

Wall Street Analyst Weigh In

GILD has been the subject of a number of research analyst reports. Royal Bank Of Canada increased their price target on shares of Gilead Sciences from $118.00 to $123.00 and gave the stock a "sector perform" rating in a research report on Tuesday, April 7th. Cantor Fitzgerald reduced their price target on shares of Gilead Sciences from $155.00 to $115.00 and set an "overweight" rating for the company in a research report on Friday, April 10th. Sanford C. Bernstein reissued an "outperform" rating and issued a $160.00 price target on shares of Gilead Sciences in a research report on Wednesday, February 11th. Scotiabank increased their price target on shares of Gilead Sciences from $140.00 to $177.00 and gave the stock a "sector outperform" rating in a research report on Wednesday, February 11th. Finally, Truist Financial increased their price objective on Gilead Sciences from $145.00 to $152.00 and gave the stock a "buy" rating in a report on Wednesday, February 11th. Twenty-four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $157.35.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.